{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:51Z","timestamp":1791237831081,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>CDK12 loss-of-function (LOF) genomic alterations are associated with focal tandem duplications (FTDs) in ovarian and prostate cancers. Because these FTDs may produce fusion-induced neoantigens (FINAs), CDK12 alteration is a candidate biomarker for immune checkpoint inhibitor sensitivity. Here we determine the prevalence of CDK12-LOF alterations and their association with FTDs across diverse tumor types.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A total of 142,133 tumor samples comprising 379 cancer types were sequenced (August 2014 to April 2018) by hybrid capture-based comprehensive genomic profiling (Foundation Medicine, Cambridge, MA) as part of routine clinical care. Results were analyzed for base substitutions, short insertions\/deletions, rearrangements, and copy number alterations. CDK12-LOF genomic alterations were assessed for zygosity status and association with FTDs\/focal copy number gain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CDK12 genomic alterations were detected in 1.1% of all cases, most frequently in prostate cancer (5.6%), but were also observed at &amp;gt;1% frequency in 11 cancer types. Across multiple cancer types, including prostate, gastric\/esophageal, ovarian, breast, and endometrial cancer, the number of FTDs was significantly increased in CDK12-LOF versus CDK12 wild-type cases. Notably, CDK12-LOF was not consistently associated with a homologous recombination deficiency genomic signature. Quantitative assessment of CDK12-associated FTDs by measurement of single copy number gains identified novel likely deleterious CDK12 kinase-domain mutations in prostate and ovarian cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Detection of CDK12-LOF genomic alterations and their association with FTDs in a diverse spectrum of malignancies suggests that immunotherapy approaches targeting FINAs derived from CDK12-associated FTDs may be a broadly applicable strategy that could be explored across cancer types in a tumor-agnostic manner.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>CDK12 inactivation in ovarian and prostate cancer results in the generation of focal tandem duplications, which can cause fusion-induced neoantigens. In prostate cancer, CDK12 alterations have demonstrated promise as a potential predictive biomarker for response to immune checkpoint blockade. This study evaluated genomic profiling data from &amp;gt;142,000 tumors to determine the prevalence of CDK12 loss-of-function genomic alterations across tumor types and demonstrated that CDK12 alterations are associated with the tandem-duplicator phenotype in cancer types other than ovarian and prostate cancer. The association of CDK12 alterations with focal tandem duplications across broad cancer types suggests that CDK12 inactivation warrants further investigation as a pan-cancer biomarker for immunotherapy benefit.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0214","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T18:35:13Z","timestamp":1562783713000},"page":"1526-1533","source":"Crossref","is-referenced-by-count":73,"title":["Pan-Cancer Analysis of <i>CDK12<\/i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype"],"prefix":"10.1093","volume":"24","author":[{"given":"Ethan S.","family":"Sokol","sequence":"first","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"},{"name":"Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew M.","family":"Pardoll","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon H.","family":"Chung","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"2021122508135581000_onco13037-bib-0001","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"2021122508135581000_onco13037-bib-0002","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2021122508135581000_onco13037-bib-0003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"key":"2021122508135581000_onco13037-bib-0004","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMcibr1808772","article-title":"Cyclin-dependent kinase 12, immunity, and prostate cancer","volume":"379","author":"Antonarakis","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122508135581000_onco13037-bib-0005","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1101\/gad.1968210","article-title":"CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1","volume":"24","author":"Bartkowiak","year":"2010","journal-title":"Genes Dev"},{"key":"2021122508135581000_onco13037-bib-0006","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev"},{"key":"2021122508135581000_onco13037-bib-0007","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res"},{"issue":"suppl 8","key":"2021122508135581000_onco13037-bib-0008","article-title":"793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations","volume":"29","author":"Abida","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122508135581000_onco13037-bib-0009","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1158\/0008-5472.CAN-15-2128","article-title":"Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications","volume":"76","author":"Popova","year":"2016","journal-title":"Cancer Res"},{"key":"2021122508135581000_onco13037-bib-0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2018.06.008","article-title":"The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations","volume":"34","author":"Menghi","year":"2018","journal-title":"Cancer Cell"},{"key":"2021122508135581000_onco13037-bib-0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2021122508135581000_onco13037-bib-0012","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1158\/0008-5472.CAN-16-2479","article-title":"High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis","volume":"77","author":"Hartmaier","year":"2017","journal-title":"Cancer Res"},{"key":"2021122508135581000_onco13037-bib-0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"2021122508135581000_onco13037-bib-0014","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122508135581000_onco13037-bib-0015","doi-asserted-by":"crossref","first-page":"17122","DOI":"10.1038\/srep17122","article-title":"Structures of the CDK12\/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding","volume":"5","author":"Dixon-Clarke","year":"2015","journal-title":"Sci Rep"},{"key":"2021122508135581000_onco13037-bib-0016","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: An emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J Clin Pathol"},{"key":"2021122508135581000_onco13037-bib-0017","article-title":"Precision oncology in solid tumors: A longitudinal tertiary care center experience","author":"Sadaps","journal-title":"JCO Precis Oncol"},{"key":"2021122508135581000_onco13037-bib-0018","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non\u2013small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"2021122508135581000_onco13037-bib-0019","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122508135581000_onco13037-bib-0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0214","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/1526\/41919125\/oncolo_24_12_1526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/1526\/41919125\/oncolo_24_12_1526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:15:01Z","timestamp":1640420101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/12\/1526\/6439535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,7,10]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0214","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,7,10]]}}}